RNAseq Analysis of Novel 1,3,4-Oxadiazole Chalcogen Analogues Reveals Anti-Tubulin Properties on Cancer Cell Lines.
RNAseq
cancer
chemotherapy
microtubule
oxadiazole
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
09 Jul 2023
09 Jul 2023
Historique:
received:
16
05
2023
revised:
30
06
2023
accepted:
04
07
2023
medline:
31
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
1,3,4-Oxadiazole derivatives are among the most studied anticancer drugs. Previous studies have analyzed the action of different 1,3,4-oxadiazole derivatives and their effects on cancer cells. This study investigated the characterization of two new compounds named
Identifiants
pubmed: 37511023
pii: ijms241411263
doi: 10.3390/ijms241411263
pmc: PMC10379353
pii:
doi:
Substances chimiques
Tubulin
0
1,3,4-oxadiazole
20O2F20OUR
Antineoplastic Agents
0
Tubulin Modulators
0
Chalcogens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Nat Prod Rep. 2014 Mar;31(3):335-55
pubmed: 24481420
Proc Natl Acad Sci U S A. 2019 May 14;116(20):9859-9864
pubmed: 31036638
Cold Spring Harb Perspect Biol. 2018 Jun 1;10(6):
pubmed: 29858272
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nat Rev Neurosci. 2009 May;10(5):319-32
pubmed: 19377501
Cell Motil Cytoskeleton. 2006 Nov;63(11):681-95
pubmed: 17009328
Cells. 2019 Aug 01;8(8):
pubmed: 31375012
Pharmaceuticals (Basel). 2020 Jan 03;13(1):
pubmed: 31947889
Anticancer Agents Med Chem. 2017;17(1):67-74
pubmed: 27141880
Protein Cell. 2013 Apr;4(4):266-76
pubmed: 23549612
Sci Rep. 2021 Sep 28;11(1):19261
pubmed: 34584128
J Nat Prod. 2019 Mar 22;82(3):680-685
pubmed: 30835122
Anticancer Agents Med Chem. 2020;20(7):758-767
pubmed: 32013835
Molecules. 2018 Dec 18;23(12):
pubmed: 30567416
Eur J Med Chem. 2022 Aug 5;238:114440
pubmed: 35576700
Mol Carcinog. 2016 Nov;55(11):1667-1677
pubmed: 26495772
Curr Top Med Chem. 2017;17(22):2523-2537
pubmed: 28056738
Cancer Inform. 2022 Apr 2;21:11769351221087046
pubmed: 35392296
Cold Spring Harb Perspect Biol. 2018 Jul 2;10(7):
pubmed: 29967009
Nat Rev Cancer. 2010 Mar;10(3):194-204
pubmed: 20147901
Pharm Res. 2012 Nov;29(11):2943-71
pubmed: 22814904
Front Pharmacol. 2022 Sep 15;13:969183
pubmed: 36188585
Sci Rep. 2018 Aug 9;8(1):11926
pubmed: 30093705
J Cell Physiol. 2021 May;236(5):3789-3799
pubmed: 33089499
Cancer Res. 2018 Jan 1;78(1):265-277
pubmed: 29180476
Br J Cancer. 2020 Feb;122(4):517-527
pubmed: 31844184
Br J Cancer. 2022 Apr;126(7):1067-1081
pubmed: 34963702
Nat Rev Drug Discov. 2010 Oct;9(10):790-803
pubmed: 20885410
Cold Spring Harb Perspect Biol. 2017 May 1;9(5):
pubmed: 28461574
Chem Biol Interact. 2019 Oct 1;312:108813
pubmed: 31494105
Drug Discov Today Technol. 2015 Aug;15:17-22
pubmed: 26464086
J Med Chem. 2016 Dec 8;59(23):10451-10469
pubmed: 27801583
Eur J Med Chem. 2013 Feb;60:23-8
pubmed: 23279864
Nat Rev Cancer. 2004 Apr;4(4):253-65
pubmed: 15057285
eNeuro. 2020 Apr 27;7(2):
pubmed: 32184299